Yüklüyor......
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long‐Term Extension Studies of Tofacitinib in Patients With Rheumatoid Arthritis
OBJECTIVE: Tofacitinib is an oral JAK inhibitor for the treatment of rheumatoid arthritis (RA). This study was undertaken to evaluate the risk of major adverse cardiovascular events (MACE) in patients with RA receiving tofacitinib. METHODS: Data were pooled from patients with moderately to severely...
Kaydedildi:
| Yayımlandı: | Arthritis Rheumatol |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
John Wiley and Sons Inc.
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6754249/ https://ncbi.nlm.nih.gov/pubmed/31385441 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/art.40911 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|